Photocure ASA: Results for the first quarter of 2021
Oslo, Norway, 19 May 2021: Photocure ASA (OSE:PHO), the Bladder Cancer Company, today reported Hexvix[®]/Cysview[®] revenues of NOK 81.6 million in the first quarter of 2021 (Q1 2020: NOK 54.4 million), and EBITDA of NOK 18.1 million (NOK -4.8 million), following the continued successful launch in markets previously operated by Ipsen Pharma SAS. The third Covid-19 wave impacted operations in the quarter, but a strong March performance indicates the environment is improving.“For the first quarter of 2021, Photocure delivered a 50% YoY increase in Hexvix/Cysview sales, unit growth in our U.S.